Moderna Investors Should Focus on This

By Scott Lee • Wednesday, October 04 12:13 • Permanent Link

Is it worth buying Moderna stock at a price of $103.28? If this question is on your mind, make sure to check out the fundamentals of this Biotechnology large-cap company:

Moderna has logged a -18.0% 52 week change, compared to 13.0% for the S&P 500
MRNA has an average analyst rating of buy and is -43.05% away from its mean target price of $181.35 per share
Its trailing earnings per share (EPS) is $2.96, which brings its trailing Price to Earnings (P/E) ratio to 34.9. The Health Care sector's average P/E ratio is 24.45
The company's forward earnings per share (EPS) is $-5.17 and its forward P/E ratio is -20.0
The company has a Price to Book (P/B) ratio of 2.32 in contrast to the Health Care sector's average P/B ratio is 4.16
The current ratio is currently 2.7, which consists in its liquid assets divided by any liabilities due within in the next 12 months
The company's free cash flow for the last fiscal year was $5.38 Billion and the average free cash flow growth rate is 0.0%
Moderna's revenues have an average growth rate of 0.0% with operating expenses growing at -51.8%. The company's current operating margins stand at 48.9%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.